Efficacy and Safety of Atacicept in IgA Nephropathy
Public ClinicalTrials.gov record NCT02808429. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA Nephropathy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This main purpose of this study was to evaluate the safety, tolerability, dose response and efficacy of Atacicept in participants with IgA nephropathy and persistent proteinuria. The study hypothesis was that treatment with Atacicept would reduce proteinuria compared to placebo.
Study identification
- NCT ID
- NCT02808429
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 16 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 30, 2017
- Primary completion
- Feb 6, 2020
- Completion
- Feb 6, 2020
- Last update posted
- Feb 24, 2021
2017 – 2020
United States locations
- U.S. sites
- 16
- U.S. states
- 15
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| AKDHC Medical Research Services, LLC. | Glendale | Arizona | 85308 | — |
| California Institute of Renal Research - Chula Vista Location | Chula Vista | California | 91910 | — |
| Colorado Kidney Care PC - Dr. Marder | Denver | Colorado | 80218 | — |
| Medical Faculty Associates | Washington D.C. | District of Columbia | 20037 | — |
| Southeastern Clinical Research Institute, LLC | Augusta | Georgia | 30909 | — |
| GA Nephrology Associates | Lawrenceville | Georgia | 30046 | — |
| Ochsner Clinic Foundation | New Orleans | Louisiana | 70121 | — |
| The Johns Hopkins Hospital | Baltimore | Maryland | 21287 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Brookview Hills Research Associates, LLC | Winston-Salem | North Carolina | 27103 | — |
| Ohio State University Clinical Trials Management Office - Ohio State CTMO Parent | Columbus | Ohio | 43210 | — |
| Northeast Clinical Research Center, LLC | Bethlehem | Pennsylvania | 18017 | — |
| Southeast Renal Research Institute | Chattanooga | Tennessee | 37404 | — |
| Nephrotex Research Group | Dallas | Texas | 75231 | — |
| Providence Sacred Heart Medical Center & Children's Hospital | Spokane | Washington | 99204 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
Recently updated IgA Nephropathy trials
Other public records listing IgA Nephropathy. Sorted by last update posted; newest first. Not a recommendation.
- NCT06419205: A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G Recruiting
- NCT07498335: Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN Recruiting
- NCT07541287: A Study of JADE101 in Participants With Immunoglobulin A Nephropathy Recruiting
- NCT07054684: Study of BHV-1400 in IgA Nephropathy Recruiting
- NCT04573478: Atrasentan in Patients With IgA Nephropathy Active, not recruiting
- NCT05852938: A Study of Zigakibart in Adults With IgA Nephropathy Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02808429, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 24, 2021 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02808429 live on ClinicalTrials.gov.